• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT].

作者信息

Suemasu K, Nomoto C, Higashi Y

出版信息

Gan To Kagaku Ryoho. 1982 Apr;9(4):667-71.

PMID:6820904
Abstract

A preoperative adjuvant chemotherapy for the prevention of recurrence of breast cancer is necessary. We administrated UFT orally at 600 mg/day to 87 patients with primary breast cancer and measured the 5-FU level in the tissue and blood. The mean blood level of 5-FU after administration was 0.073 mcg/ml at one hr, 0.081 mcg/ml at 2 hrs, 0.043 mcg/ml at 3 hrs and remained significantly after 5 hrs (0.031 mcg/ml). The mean 5-FU level in the dominant vessels of the breast was also significantly high. The mean tumor 5-FU level was 0.22 mcg/g (0.025-0.768) and normal breast tissue level was 0.048 mcg/g (0.011-0.394). This showed significantly high tumor 5-FU level compared with that of normal (p less than 0.001). In comparison of 5-FU levels with tumor sizes of T1, T2 and T3 and histological patterns (papillotubular, medullary tubular and scinhous) not significant difference was observed. The mean metastatic lymph node level of 5-FU was 0.193 mcg/g (0.070-0.789) and normal lymph node level was 0.093 mcg/g (0.008-0.210) (p less than 0.05). In conclusion, preoperative administration of UFT was considered to be very effective for the primary breast cancer because of high tumor affinity of 5-FU.

摘要

相似文献

1
[Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT].
Gan To Kagaku Ryoho. 1982 Apr;9(4):667-71.
2
[Level of 5-FU in tumor tissues of the patients with head and neck malignant tumors after oral administration of UFT].
Gan To Kagaku Ryoho. 1983 Aug;10(8):1796-802.
3
[5-FU concentration in the tissues (tumor and lymph node) of breast cancer patients given preoperative administration of UFT and FT].[术前给予优福定(UFT)和替加氟(FT)的乳腺癌患者组织(肿瘤和淋巴结)中的5-氟尿嘧啶浓度]
Gan To Kagaku Ryoho. 1985 May;12(5):1147-51.
4
[Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].替加氟-尿嘧啶肠溶颗粒剂在癌症患者中的药代动力学及Ⅰ期研究
Gan To Kagaku Ryoho. 1983 Dec;10(12):2565-72.
5
[5-FU concentration in blood and tissue of patients with primary lung cancer after oral administration of UFT].口服优福定后原发性肺癌患者血液及组织中5-氟尿嘧啶的浓度
Gan To Kagaku Ryoho. 1986 Mar;13(3 Pt 1):525-30.
6
[5-FU, FT-207 and uracil concentrations in the serum and tissues of patients with cervical cancer after UFT oral administration].[口服优福定后宫颈癌患者血清及组织中5-氟尿嘧啶、替加氟及尿嘧啶的浓度]
Gan To Kagaku Ryoho. 1986 Feb;13(2):349-55.
7
[The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
Gan To Kagaku Ryoho. 1988 Aug;15(8):2319-23.
8
[5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur].
Gan To Kagaku Ryoho. 1986 Aug;13(8):2618-24.
9
[5-FU concentration in tissues of gastric cancer patients with preoperative administration of UFT--especially in comparison with FT-207].
Gan No Rinsho. 1985 Oct;31(13):1697-703.
10
[UFT concentration in various tissues from cancer patients].
Gan To Kagaku Ryoho. 1983 Oct;10(10):2130-8.

引用本文的文献

1
Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.通过有意的药物-药物相互作用来提高抗癌药物的口服生物利用度。
Basic Clin Pharmacol Toxicol. 2022 Jan;130 Suppl 1(Suppl 1):23-35. doi: 10.1111/bcpt.13623. Epub 2021 Jun 28.
2
'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.一项关于口服尿嘧啶/替加氟(UFT)联合亚叶酸钙并与奥沙利铂联合使用(TEGAFOX)作为转移性结直肠癌患者一线治疗的II期研究
Br J Cancer. 2006 Jan 16;94(1):69-73. doi: 10.1038/sj.bjc.6602913.
3
Oral tegafur/uracil.
口服替加氟/尿嘧啶。
Drugs Aging. 2001;18(12):935-48; discussion 949-50. doi: 10.2165/00002512-200118120-00005.
4
Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.替加氟/尿嘧啶联合亚叶酸钙治疗结直肠癌:氟尿嘧啶的双重调节作用
Drugs. 1999;58 Suppl 3:77-83. doi: 10.2165/00003495-199958003-00011.
5
Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.尿嘧啶替加氟(UFT)联合口服亚叶酸钙的I期试验:14天方案。
Invest New Drugs. 1997;15(2):123-8. doi: 10.1023/a:1005808822565.